Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC

Abstract

Background High circulating levels of cellular adhesion molecules (CAMs) in non‐small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre‐treatment levels of CAMs in previously treated patients receiving nivolumab for NSCLC. Materials and methods Seventy one patients with advanced NSCLC, treated with nivolumab at the dose of 3 mg/kg every 14 days, were enrolled. Maximum follow‐up time was 3 years. Serum levels of Vascular Cell Adhesion Molecule‐1 (VCAM‐1) and Intracellular Adhesion Molecule‐1 (ICAM‐1) were measured at baseline and before each nivolumab administration. Endpoints of the study were a composite outcome of survival ≥2 years or absence of disease progression at the end of the follow‐up, and the overall survival. Results Composite outcome and overall survival were positively associated with VCAM‐1 baseline levels and with the reduction of VCAM‐1 during the treatment. After adjustment for potential confounders, the change in VCAM‐1 serum levels during the treatment was an independent predictor of overall survival. Conclusions High baseline serum levels of VCAM‐1 are associated with a longer survival in patients treated with nivolumab as second line treatment for NSCLC. Surviving patients experience also a significant reduction in CAMs expression during the treatment. Hence, CAMs might be promising prognostic factors in patients with NSCLC underoing immunotherapy.

Immunomodulatory Effect of Traditional Chinese Medicine Combined with Systemic Therapy on Patients with Liver Cancer: A Systemic Review and Network Meta-analysis

“…Because the sample size is small and the quality of evidence is not high, to follow-up extensive clinical trials are still required to confirm this conclusion. In addition, VEGF [44], ICAM-1 [45][46][47], TGF-β [48], IL-2, IL-6 [49][50][51], and TNF-α [52] play an important role in the growth and metastasis of tumor cells, and can affect the expression of co-inhibitory molecules on immune cells. In this NMA study, compared with ST alone, combined TCM can significantly reduce the expression of VEGF, ICAM-1, IL-6, and TGF-β levels, thus improving the immunity of liver cancer patients.…”

Neutrophil degranulation, endothelial and metabolic dysfunction in unvaccinated long COVID patients

“…The lower limits of detection were 15.63 pg/mL for VCAM‐1, 31.25 pg/mL for MMP‐9, resistin, leptin and ICAM‐1, 62.5 pg/mL for MMP‐8, MPO and osteopontin, 93.75 pg/mL for E‐selectin, 78.13 pg/mL for L‐selectin and 125 pg/mL for P‐selectin. The mean intra‐ and inter‐assay coefficients of variation below 8%, as previously reported 30 …”

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application

“…The levels of serum VCAM-1 are significantly higher in NSCLC patients, which be a potential auxiliary biomarker ( 133 ). High baseline serum levels of VCAM-1 are related to better prognosis in NSCLC patients treated by second line nivolumab and may also be a potential biomarker for anti-PD-1 therapy ( 134 ).…”